GHK-Cu research: what the studies actually show

GHK-Cu research rests mostly on cell culture and animal wound studies, plus a handful of small, short cosmetic studies in women, several of which exist only as conference abstracts. GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, first reported from human plasma in 1973. Reviews describe it as active in fibroblast and rat wound models, but a 2024 review in BioImpacts found "a surprising absence of clinical studies" and noted that no studies had been published on its possible side effects. This page sorts the copper peptide studies by evidence level so you can see what each one can and cannot tell you.

Where GHK-Cu came from

Loren Pickart reported GHK in 1973 after finding that a factor in plasma from young donors made older liver tissue behave more like young tissue. The peptide binds copper(II), which led to an early "copper hypothesis" for its activity. According to Pickart and Margolina's 2018 review, plasma GHK falls with age, from about 200 ng/mL at age 20 to about 80 ng/mL by age 60. That decline is often quoted online, but it is an observation about concentration, not evidence that adding GHK-Cu does anything.

One point to keep in mind throughout: both authors of that review were affiliated with Skin Biology, a company with commercial interests in GHK-Cu, and the gene-expression analyses it reports were run by the authors themselves. For background on the molecule itself, see our GHK-Cu reference page.

The evidence, sorted by level

Cell studies: the bulk of GHK-Cu evidence

Most mechanistic claims come from cells in a dish, where GHK-Cu has been studied for effects on collagen and other skin-matrix readouts. The 2024 BioImpacts review concluded that "based on cellular studies" GHK can be considered an anti-wrinkle ingredient, but it was explicit that this is an inference from in-vitro work.

The most cited figure online comes from Connectivity Map analysis, a database of how compounds shift gene expression in human cell lines. Pickart and Margolina reported that GHK changed the expression of 31.2% of human genes by 50% or more, with 59% of those increased and 41% decreased. These are computational analyses of cell-line data run by the review's own authors. They describe a pattern in a dataset, not effects in people, and the authors themselves noted that compounds analyzed this way "often lack supporting biological data."

Animal studies: wound models

The strongest animal paper is Maquart and colleagues' 1993 study in the Journal of Clinical Investigation. Researchers implanted stainless-steel mesh chambers under the skin of rats and injected saline or GHK-Cu into them. GHK-Cu produced a concentration-dependent increase in dry weight, DNA, total protein, collagen and glycosaminoglycans in the chambers, and raised type I and type III collagen mRNA. A control tripeptide had no significant effect, which strengthens the finding within that model.

Other animal work summarized in the 2018 review includes:

• Rabbits: open wounds treated with a topical tripeptide-copper complex, alone or with laser light, with reported changes in wound contraction, granulation tissue and blood-vessel growth.
• Rats, healthy and diabetic: a collagen dressing containing GHK, with collagen reported to rise 9-fold in healthy rats.
• Rats with ischemic wounds: faster closure and lower MMP-2, MMP-9 and TNF-β than controls (Canapp 2003).

These are wound-repair models in damaged tissue. They say little about intact human skin, hair or anything systemic. The same pattern of model-specific animal evidence applies to other repair peptides; compare our BPC-157 vs TB-500 explainer.

Human studies: small and cosmetic

The human evidence is thin, and the details matter:

• 1998 pilot (Abdulghani et al.): about 20 volunteers. Procollagen production increased in 70% of those using GHK-Cu cream, 50% with vitamin C cream and 40% with retinoic acid. The BioImpacts review notes the very small sample and no described randomization or blinding.
• Leyden et al. 2002: a 12-week facial cream study in 71 women and a 12-week eye cream study in 41 women. Both were presented at a dermatology meeting and cited as conference proceedings, not full peer-reviewed papers, so the full methods and data are not available.
• 8-week serum study: a randomized, double-blind study in women compared a GHK-Cu nano-lipid formulation with Matrixyl 3000 and a control serum, reporting a 31.6% greater reduction in wrinkle volume than Matrixyl 3000. The 2018 review does not state how many participants took part.

None of these is a large, independent, registered trial. They measured cosmetic skin parameters over weeks, in women only, and several cannot be checked in full. For how GHK-Cu and palmitoyl pentapeptides compare on this kind of evidence, see GHK-Cu vs Matrixyl and the Matrixyl reference page.

The gaps: penetration, stability and safety

The 2024 review focused on why lab results may not carry over to skin:

• Penetration: GHK is charged at physiological pH. In one in-vitro test on human skin, only 0.006% of applied GHK-Cu crossed intact epidermis. Another study found no peptide or copper permeated intact human skin unless it was pretreated with microneedles.
• Stability: under forced degradation, oxidation was the most damaging condition; only 84.2% of GHK-Cu remained after one hour at 22 °C in 0.5% hydrogen peroxide. GHK is also broken down by carboxypeptidase enzymes.
• Safety: the review found that "no studies have been published on the possible side effects of these peptides."

For general risks of unregulated synthetic peptides, see synthetic peptide safety risks.

What this means for lab work

For in-vitro researchers, the stability data are the practical takeaway: protect GHK-Cu solutions from oxidizing conditions, and verify identity and copper content on a certificate of analysis before relying on results. The peptide calculator handles stock-solution molarity. On regulation, GHK-Cu is not among the peptides covered by the October 2026 HHS compounding policy.

Frequently asked questions

Sources

1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018;19(7):1987
2. Mortazavi SM et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts (online April 2024)
3. Maquart FX et al. In vivo stimulation of connective tissue accumulation by GHK-Cu in rat experimental wounds. J Clin Invest 1993;92(5):2368–2376